Adnexal Diseases |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
NCT02487693: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma |
|
|
| Active, not recruiting | 2 | 50 | RoW | Radiofrequency ablation, RFA, Cytokine-induced killer cells, CIK | The First People's Hospital of Changzhou | Ovarian Carcinoma | 06/38 | 06/40 | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
|
|
| No Longer Available | N/A | | Japan | olaparib | AstraZeneca | PSR Ovarian Cancer With a BRCA Mutation | | | | |
NCT02686463: Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy |
|
|
| Not yet recruiting | N/A | 150 | RoW | Laparoscopy, Laparotomy | Shengjing Hospital | Ovarian Cancer | 06/18 | 06/23 | | |
NCT03006939: Fluid Balance During Surgery for Ovarian Cancer |
|
|
| Recruiting | N/A | 60 | Europe | Cytoreductive surgery | University Hospital, Bonn | Ovarian Neoplasm, Fluid Therapy | 12/19 | 12/22 | | |
| Recruiting | N/A | 200 | RoW | | Kangbuk Samsung Hospital | Inflammatory Pelvic Disease | 09/24 | 09/24 | | |
NCT02869568: Institut Paoli Calmettes Ovarian Cancer Database |
|
|
| Recruiting | N/A | 6000 | Europe | Data collection | Institut Paoli-Calmettes | Ovarian Neoplasms | 01/30 | 12/30 | | |
| Recruiting | N/A | 3000 | RoW | | Kangbuk Samsung Hospital | Ovarian Neoplasms | 12/40 | 12/40 | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Not yet recruiting | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/00 | | | |